In Vivo Reversible Programming of T cells with SAIL’s Targeted NP-eRNA Platform for Treatment of Autoimmune Diseases & Beyond
Time: 1:30 pm
day: Conference Day Two
Details:
• Enabling in vivo reversible programming of T cells with SAIL’s targeted LNP-eRNA technology platform
• Replacing a complex, costly, and genome-integrative cell therapy product with an off-the-shelf, and non-integrative IV injectable product by encoding a CAR specific for hCD19 directly in the patient’s T cells in vivo
• Advancing a first-generation in situ CAR product for AID to human clinical studies while in parallel advancing next-generation in vivo reprogramming medicines
New Data
